# US 2019/0316124 A1 · Semaphorin 3d and plexin d1 as therapeutic targets for pancreatic cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316124 A1
- Document ID: US20190316124A1
- Status: Published application
- Kind: A1
- Application number: 16/320,632
- Filed: 2017-07-27
- Published: 2019-10-17
- Earliest claimed: 2016-07-27
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Lei Zheng
- Web page: https://patentgrep.com/patent/US20190316124A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/04: specific for metastasis
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/57525: of the liver or pancreas
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/122: Hairpin
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention features compositions and methods for treating and preventing pancreatic cancer.

## Claims

### Claim 1

A method of reducing or inhibiting tumor invasion or tumor metastatic progression in a subject comprising:
identifying a subject having or at risk of developing cancer; and
administering to the subject an effective amount of an agent that reduces the transcription or activity of Semaphorin,
thereby reducing or inhibiting tumor invasion or tumor metastatic progression in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said Semaphorin comprises Semaphorin 3D (Sema3D).

### Claim 3 (depends on 2)

The method of claim 2, wherein said agent that reduces the transcription or activity of Sema3D comprises a small molecule inhibitor, an antibody or a fragment thereof, or a nucleic acid molecule.

### Claim 4 (depends on 3)

The method of claim 3, wherein nucleic acid molecule comprises double stranded ribonucleic acid (dsRNA), small hairpin RNA or short hairpin RNA (shRNA), or antisense RNA, or any portion thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said agent that reduces the transcription or activity of Sema3D is administered at a dose of 1 mg/kg/day-1 g/kg/day.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering an agent that reduces the transcription or activity of plexin to said subject.

### Claim 7 (depends on 4)

The method of claim 4, wherein said plexin comprises plexin D1 (PlxnD1).

### Claim 8 (depends on 5)

The method of claim 5, wherein said PlxnD1 inhibitor comprises an anti-PlxnD1 antibody.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering an agent that reduces the transcription or activity of ANXA2 to said subject.

### Claim 10 (depends on 7)

The method of claim 7, wherein the ANXA2 inhibitor comprises an anti-ANXA2 antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has had the bulk of the tumor resected.

### Claim 12 (depends on 1)

The method of claim 1, wherein said cancer comprises a gastrointestinal cancer.

### Claim 13 (depends on 10)

The method of claim 10, wherein said cancer comprises pancreatic cancer.

### Claim 14 (depends on 11)

The method of claim 11, wherein said pancreatic cancer comprises a pancreatic ductal adenocarcinoma (PDA).

### Claim 15 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 16 (depends on 1)

The method of claim 1, wherein said agent that reduces the transcription or activity of Sema3D and said agent that reduces the transcription or activity of PlxnD1 are administered simultaneously.

### Claim 17 (depends on 1)

The method of claim 1, wherein said agent that reduces the transcription or activity of Sema3D and said agent that reduces the transcription or activity of PlxnD1 are administered sequentially.

### Claim 18 (depends on 19)

The method of claim 19, wherein said agent that reduces the transcription or activity of Sema3D and said agent that reduces the transcription or activity of PlxnD1 are administered twice per week.

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering an anti-cancer agent to said subject.

### Claim 20 (depends on 1)

The method of claim 1, wherein said agent that reduces the transcription or activity of Sema3D is administered orally, intravenously, intramuscularly, systemically, subcutaneously or by inhalation.

### Claim 21 (depends on 1)

The method of claim 1, wherein the composition is administered in a form selected from the group consisting of pills, capsules, tablets, granules, powders, salts, crystals, liquids, serums, syrups, suspensions, gels, creams, pastes, films, patches, and vapors.

### Claim 22

A method of screening for a candidate compound which inhibits tumor invasion and/or tumor metastasis, comprising:
contacting a candidate compound with a pancreatic cancer cell;
determining a Sema3D secretion level; and
identifying the candidate compound as a candidate compound for inhibiting tumor invasion and/or tumor metastasis if the candidate compound inhibits secretion of Sema3D.

### Claim 23

A method of determining whether pancreatic cancer will metastasize in a subject comprising
obtaining a pancreatic tumor sample from a subject;
determining a level of Sema3D in said tumor sample;
comparing said level of Sema3D in said tumor sample to a control level of Sema3D, wherein an increased level of Sema3D in said tumor sample relative to the control level of Sema3D indicates said pancreatic cancer will metastasize in said subject.

### Claim 24 (depends on 23)

The method of claim 23, further comprising administering to the subject an effective amount of an agent that reduces the transcription or activity of Sema3D, thereby reducing or inhibiting tumor invasion or tumor metastatic progression in said subject.
